Neogen (NEOG) director reports 19,769 shares, 50,814 options grant
Neogen (NEOG) filed a Form 4 reporting director equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Neogen (NEOG) filed a Form 4 reporting director equity awards. On 10/23/2025, the reporting person acquired 19,769 shares of common stock at $6.07. Following this, directly held common stock totaled 36,788 shares.
The filing also reports 50,814 stock options granted at an exercise price of $6.07, expiring on 10/23/2035, with 50,814 derivative securities beneficially owned after the transaction. Per the footnote, options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock (Right to Buy) | 50,814 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 19,769 | $6.07 | $120K |
Footnotes (1)
- F1. Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NEOG's Form 4 disclose?
What are the terms of the NEOG stock options reported?
How do the NEOG awards vest?
Was the filing made by one or more reporting persons?
What is the ownership form noted for the reported holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.